Test Price
2,800 AEDโ Home Collection Available
๐ Results in 3 to 4 weeks from sample receipt
GNAS Gene Pseudohypoparathyroidism Type 1A Genetic Test in UAE | 2800 AED | DHA Licensed
Executive Summary & Core Metrics
- โขAccuracy Guarantee: 99.9% diagnostic sensitivity via ISO 15189-accredited NGS processing.
- โขPremium Logistics: VIP mobile phlebotomy and temperature-controlled cold-chain home collection available daily 8 AM โ 11 PM.
- โขClinical Guidance: Telephonic post-test clinical guidance for result interpretation by a consultant medical geneticist.
- โขInsurance: Direct billing verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The GNAS Gene Pseudohypoparathyroidism Type 1A NGS Test uses next-generation sequencing to identify pathogenic variants in the GNAS gene. This analysis covers the entire coding region and splice sites, enabling definitive molecular diagnosis of pseudohypoparathyroidism type 1A. The test is indicated for patients with clinical features of Albright's hereditary osteodystrophy, hormone resistance, or unexplained hypocalcemia.
| Feature | Our Test | Closest Alternative |
|---|---|---|
| Precision | Full-gene NGS coverage with copy-number analysis | Single-gene Sanger sequencing (limited to known hotspots) |
| Methodology | Next-Generation Sequencing (NGS) | Targeted Mutation Panel |
| Turnaround Time | 3 to 4 Weeks | 6โ8 Weeks (depending on lab) |
Physician Insight & Safety Protocols
โAs a consultant in medical genetics, I understand the complexity surrounding genetic testing for pseudohypoparathyroidism type 1A. This NGS analysis of the GNAS gene provides high-confidence molecular diagnosis, but results must always be integrated with clinical and biochemical findings. Please consult your endocrinologist or genetic counsellor for comprehensive interpretation and management.โ
โ Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Medication Safety Advisory
โ Do not discontinue prescribed medication without consulting your doctor
This genetic test is not a substitute for ongoing endocrine care. Continue all prescribed treatments (e.g., calcium, vitamin D, or hormone therapy) unless explicitly advised otherwise by your physician.
Exclusion Criteria & Emergency Red Flags
- Recent hematopoietic stem cell transplant may confound genetic analysis; consult the laboratory before testing.
- If the patient experiences severe hypocalcemic symptoms (tingling around mouth, muscle spasms, seizures, irregular heartbeat), seek emergency medical care immediately.
- This test is not validated for prenatal diagnosis in the absence of a known familial mutation. Genetic counselling is mandatory before sample collection.
Patient FAQ & Clinical Guidance
1. What is GNAS gene pseudohypoparathyroidism type 1A, and how does this test diagnose it?
Pseudohypoparathyroidism type 1A is an inherited disorder caused by inactivating mutations in the GNAS gene, leading to hormone resistance and features of Albright's hereditary osteodystrophy. This test uses next-generation sequencing to read the entire GNAS coding region, identifying single-nucleotide variants, small insertions/deletions, and copy-number changes. It provides a molecular diagnosis with >99% analytical sensitivity.
2. How long does it take to receive results, and what does the process involve?
Results are typically available in 3 to 4 weeks from the date the laboratory receives your sample (peripheral whole blood, extracted DNA, or buccal swab). The process includes pre-test genetic counselling, sample collection via our VIP mobile phlebotomy service, NGS library preparation, sequencing, bioinformatic analysis, and a final clinical report signed by a board-certified consultant medical geneticist.
3. Does insurance cover this genetic test, and what happens after a positive result?
Coverage depends on your policy; we provide direct billing verification via WhatsApp at +971 54 548 8731 and work with major UAE insurers under DHA guidelines. A positive result confirms the diagnosis and triggers genetic counselling, family screening, and personalised endocrine management, all coordinated through licensed specialists committed to UAE PDPL data privacy.
UAE Regulatory & Data Privacy Adherence
Compliance Framework
- Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) โ governs the collection, processing, and storage of genetic data.
- Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields โ regulates health information systems and cybersecurity for patient records.
- Federal Decree-Law No. 4 of 2016 on Medical Liability โ ensures patient safety, informed consent, and clinical accountability.
- Accredited under ISO 15189:2022 (Medical Laboratories) and ISO 9001:2015 (Quality Management).
Clinical & Logistical Metadata
| Test Name | GNAS Gene Pseudohypoparathyroidism Type 1A NGS Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3 to 4 weeks from sample receipt |
| Sample Type / Matrix | Peripheral whole blood (EDTA), extracted DNA, or buccal swab (Oragene DNA collection kit) |
| Methodology Used | Next-Generation Sequencing (NGS) โ full gene coding region & splice sites |
| ICD-10-CM Code | E20.1 (Pseudohypoparathyroidism) |
| LOINC Code | 48018-6 (Genetic analysis of GNAS gene) |
| DHA Facility License & Address | License No. 1143 โ Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE โ DNA Labs UAE |
ุฏุนู ุซูุงุฆู ุงููุบุฉ ู ุชุงุญ
ุงูุชุญูู ู ู ุงูุชุบุทูุฉ ุงูุชุฃู ูููุฉ
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
ุชููู ุนู ุงูุชุฎู ูู. ุฃุฑุณู ุตูุฑุฉ ู ู ุจุทุงูุฉ ุงูุชุฃู ูู ููุตูุฉ ุงูุทุจูุจ ุฅูู ูุฑูู ุงูุชุญูู ุงูู ุนุชู ุฏ ู ู ููุฆุฉ ุงูุตุญุฉ ุจุฏุจู ุนุจุฑ ุงููุงุชุณุงุจ. ุงุญุตู ุนูู ุชุญุฏูุซ ุงูุญุงูุฉ ูู ุฏูุงุฆู.
Available in Arabic, English, Hindi & Urdu
Preparation Required
["Genetic counselling is mandatory before sample collection"]
Medically Reviewed by Dr. Lina Osama Zaki Quteineh
All content reviewed by qualified professionals for accuracy.
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians